In a report released today, Thomas Smith from Leerink Partners maintained a Buy rating on Connect Biopharma Holdings (CNTB – Research Report), with a price target of $22.00. The company's shares closed last Wednesday at $5.00, close to its 52-week low of $4.10. According to TipRanks.com, Smith has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -18.3% and a 21.4% success rate. Smith covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Prometheus Biosciences, and Eledon Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Connect Biopharma Holdings.
https://www.tipranks.com/news/blurbs/leerink-partners-thinks-connect-biopharma-holdings-stock-is-going-to-recover-2?utm_source=advfn.com&utm_medium=referral
Connect Biopharma (NASDAQ:CNTB)
Historical Stock Chart
From Jul 2022 to Aug 2022 Click Here for more Connect Biopharma Charts.
Connect Biopharma (NASDAQ:CNTB)
Historical Stock Chart
From Aug 2021 to Aug 2022 Click Here for more Connect Biopharma Charts.